Search Results

You are looking at 41 - 50 of 148 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas, Rhonda Bitting, Alan Bryce, Brian Chapin, Heather H. Cheng, Anthony Victor D’Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, George Netto, Julio M. Pow-Sang, Robert Reiter, Mack Roach III, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Dorothy A. Shead, Jenna Snedeker, and Deborah A. Freedman-Cass

metastatic disease, which may be a result of declining rates of prostate specific antigen PSA testing that followed the 2012 United States Preventive Services Task Force (USPSTF) recommendations against it. 2 – 10 Researchers further estimate that prostate

Full access

Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer

Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee, and Joseph E. Ippolito

Role of Multiparametric MRI in Diagnosis Conventional screening for prostate cancer (PCa) consists of digital rectal examination (DRE) and serum prostate-specific antigen (PSA) testing, followed by transrectal ultrasound (TRUS)–guided prostate

Full access

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer

Eric Lu, George V. Thomas, Yiyi Chen, Alexander W. Wyatt, Paul Lloyd, Jack Youngren, David Quigley, Raymond Bergan, Shawna Bailey, Tomasz M. Beer, Felix Y. Feng, Eric J. Small, and Joshi J. Alumkal

provider's discretion. Outcomes and Assessment Several metrics of antitumor activity were examined, including maximal decline in prostate-specific antigen (PSA) level while on therapy, radiographic response while on therapy, and duration of

Full access

Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study

Firas Abdollah, Jesse D. Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S. Kibel, Paul L. Nguyen, Toni K. Choueiri, Kathy J. Selvaggi, Mani Menon, and Quoc-Dien Trinh

performed: laboratory studies, prostate-specific antigen (PSA) testing, cystourethroscopy, Foley catheter placement, electrocardiography, imaging, hormonal therapy, chemotherapy, and any radiotherapy. Moreover, we evaluated outpatient office visits. Second

Full access

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer

Vinayak Muralidhar, Paul J. Catalano, Gally Reznor, Brandon A. Mahal, Toni K. Choueiri, Christopher J. Sweeney, Neil E. Martin, Clair J. Beard, Yu-Wei Chen, Michelle D. Nezolosky, Karen E. Hoffman, Felix Y. Feng, Quoc-Dien Trinh, and Paul L. Nguyen

clinical stage T1c, Gleason score of 4 + 4 = 8, and prostate-specific antigen (PSA) level less than 10 ng/mL, or clinical stage T1c, Gleason score of 6, and PSA level greater than 20 ng/mL. Among patients managed with radiation, those with favorable high

Full access

Reflecting the Debates of Updating the Prostate Cancer Guidelines

James L. Mohler

Sokoll LJ . Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings . J Urol 1998 ; 160 : 2407 . 4. Cheng L Jones TD Pan CX . Anatomic

Full access

Point: Active Surveillance for Favorable Risk Prostate Cancer

Laurence Klotz

cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings . J Urol 1998 ; 160 : 2407 – 2411 . 15. Noguchi M Stamey TA McNeal JE Yemoto CM . Relationship between systematic

Full access

Counterpoint: The Case for Immediate Active Treatment

Stacy Loeb and William J. Catalona

; discussion 1302–1293 . 5. Choo R Klotz L Danjoux C . Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and

Full access

Understanding the Prostate Literature: The Need for a Multi-Disciplined Approach

Rodger J. Winn

. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for localized prostate cancer . J Clin Oncol 1999 ; 17 : 168 – 172 . 3 Kattan MW Eastham JA Stapleton AM . A

Full access

Prostate Cancer Early Detection, Version 1.2014

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shanefelt, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Maria Ho

: http://seer.cancer.gov/faststats/selections.php . Accessed March 11, 2014 . 3. Heijnsdijk EA Wever EM Auvinen A . Quality-of-life effects of prostate-specific antigen screening . N Engl J Med 2012 ; 367 : 595 – 605 . 4